Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
View Patent ↗This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.
1. A method for treating an animal having a condition characterized by a cognitive disorder or a memory disorder, comprising administering to that animal, directly or indirectly via the circulation, an effective amount of Glycyl-2-Methyl-L-Prolyl-L-Glutamate (G-2MePE) in the range of about 0.12 mg/kg to about 50 mg/kg, thereby increasing cognitive function.
2. The method of claim 1 where the condition is a memory loss or impairment associated with loss of neuronal cells.
3. The method of claim 2 , wherein said neuronal cell loss is due to apoptosis, necrosis, or neuronal degeneration.
4. The method of claim 1 where the condition is a memory loss or mild cognitive disorder.
5. The method of claim 1 where the condition is a memory disorder or impairment due to aging or a neurodegenerative condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis.
6. The method of claim 1 where the condition is a memory disorder due to hypoperfusion or hyperperfusion of the brain.
7. The method of claim 1 where the condition or memory loss is associated with type I diabetes or type II diabetes.
8. A method of enhancing cognitive function of an animal having a cognitive disorder due to aging, comprising administering the animal, either directly or indirectly via the circulation, an effective amount of G-2MePE.
9. The method of claim 1 , wherein said condition can benefit from stimulation of neurogenesis in the brain of said animal.
10. The method of claim 1 , wherein said condition can benefit from stimulation of production of neural cells containing choline acetyltransferase.
11. The method of claim 1 , where said condition is characterized by astrocytosis.
12. The method of claim 1 , wherein said G-2MePE is administered systemically, or parenterally.
13. The method of claim 1 , wherein said G-2MePE is administered via an intravenous, subcutaneous, intranasal or oral route.
14. The method of claim 1 , wherein said condition results from traumatic brain injury.
15. The method of claim 14 , wherein said traumatic brain injury is a penetrating brain injury.
16. The method of claim 6 , wherein said hypoperfusion is the result of stroke, cardiac artery bypass graft surgery (CABG), or myocardial infarction.